Arcus Biosciences Inc (RCUS) Rise 19.87% in Day Trading, Closes at $19.67

The price of Arcus Biosciences Inc (NYSE: RCUS) closed at $19.67 in the last session, up 19.87% from day before closing price of $16.41. In other words, the price has increased by $+3.26 from its previous closing price. On the day, 3513415 shares were traded. RCUS stock price reached its highest trading level at $19.96 during the session, while it also had its lowest trading level at $16.97.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

Ratios:

We take a closer look at RCUS’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 4.52 and its Current Ratio is at 4.52. In the meantime, Its Debt-to-Equity ratio is 0.26 whereas as Long-Term Debt/Eq ratio is at 0.24.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, BofA Securities on November 18, 2022, initiated with a Neutral rating and assigned the stock a target price of $33.

On October 11, 2022, Morgan Stanley started tracking the stock assigning a Overweight rating and target price of $40.

Insider Transactions:

An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jan 29 when GILEAD SCIENCES, INC. bought 15,238,095 shares for $21.00 per share. The transaction valued at 319,999,995 led to the insider holds 30,061,124 shares of the business.

Jaen Juan C. sold 6,975 shares of RCUS for $140,128 on Jan 02. The President now owns 1,215,265 shares after completing the transaction at $20.09 per share. On Jan 02, another insider, Goeltz II Robert C., who serves as the Chief Financial Officer of the company, sold 2,004 shares for $20.00 each. As a result, the insider received 40,080 and left with 51,831 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RCUS now has a Market Capitalization of 1.79B and an Enterprise Value of 1.04B. For the stock, the TTM Price-to-Sale (P/S) ratio is 12.59 while its Price-to-Book (P/B) ratio in mrq is 3.21. Its current Enterprise Value per Revenue stands at 8.88 whereas that against EBITDA is -3.57.

Stock Price History:

Over the past 52 weeks, RCUS has reached a high of $25.47, while it has fallen to a 52-week low of $12.95. The 50-Day Moving Average of the stock is 16.82, while the 200-Day Moving Average is calculated to be 18.04.

Shares Statistics:

According to the various share statistics, RCUS traded on average about 819.90K shares per day over the past 3-months and 927.21k shares per day over the past 10 days. A total of 75.50M shares are outstanding, with a floating share count of 31.21M. Insiders hold about 58.30% of the company’s shares, while institutions hold 66.06% stake in the company. Shares short for RCUS as of Jan 31, 2024 were 7M with a Short Ratio of 8.54, compared to 7.27M on Dec 29, 2023. Therefore, it implies a Short% of Shares Outstanding of 7.77% and a Short% of Float of 11.71%.

Earnings Estimates

The company has 7 analysts who recommend its stock at the moment. On average, analysts expect EPS of -$0.96 for the current quarter, with a high estimate of -$0.42 and a low estimate of -$1.34, while EPS last year was -$1.09. The consensus estimate for the next quarter is -$1.05, with high estimates of -$0.73 and low estimates of -$1.31.

Analysts are recommending an EPS of between -$1.64 and -$5.37 for the fiscal current year, implying an average EPS of -$3.42. EPS for the following year is -$4.07, with 9 analysts recommending between -$2.26 and -$6.12.

Revenue Estimates

According to 7 analysts, the current quarter’s revenue is expected to be $33.43M. It ranges from a high estimate of $72.5M to a low estimate of $25M. As of the current estimate, Arcus Biosciences Inc’s year-ago sales were $25M, an estimated increase of 33.70% from the year-ago figure. For the next quarter, 7 analysts are estimating revenue of $26.29M, a decrease of -13.20% less than the figure of $33.70% in the same quarter last year. There is a high estimate of $29.5M for the next quarter, whereas the lowest estimate is $22.5M.

A total of 10 analysts have provided revenue estimates for RCUS’s current fiscal year. The highest revenue estimate was $347.16M, while the lowest revenue estimate was $95M, resulting in an average revenue estimate of $152.31M. In the same quarter a year ago, actual revenue was $117M, up 30.20% from the average estimate. Based on 9 analysts’ estimates, the company’s revenue will be $125.19M in the next fiscal year. The high estimate is $201.96M and the low estimate is $90M. The average revenue growth estimate for next year is down -17.80% from the average revenue estimate for this year.

Most Popular